Australia markets open in 7 hours 29 minutes

Catalent Inc (0C8.SG)

Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
52.400.00 (0.00%)
As of 02:21PM CET. Market open.
Full screen
Previous close52.40
Open52.00
Bid51.80 x 300000
Ask52.50 x 300000
Day's range52.00 - 52.40
52-week range29.20 - 67.27
Volume0
Avg. volume38
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings date17 May 2024 - 21 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Zacks

    Catalent (CTLT) Q2 Earnings Lag Estimates, Gross Margin Down

    Catalent (CTLT) reports lower revenues in Biologics segments in its second-quarter fiscal 2024, resulting in overall soft performance.

  • Zacks

    Catalent (CTLT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

    Although the revenue and EPS for Catalent (CTLT) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

  • Reuters

    UPDATE 3-Catalent sales edge past estimates as focus shifts to Novo deal

    Contract drug manufacturer Catalent inched past Wall Street estimates for second-quarter revenue on Friday, days after it agreed to a $16.5-billion buyout offer from Novo Nordisk's parent firm. The New Jersey-based firm is the main supplier of fill-finish work - involving filling and packaging syringes and injection pens in sterile conditions - for Novo's popular weight-loss drug, Wegovy. Catalent's shares were marginally higher at $56.70, compared with Novo's offer of $63.50 per share.